References: Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet. 2020;395(10232):1268–77. (PMID: 10.1016/S0140-6736(20)30415-3321458257181180)
Luo Y, Feng B, Wei D, Han Y, Li M, Zhao J, et al. Adjuvant chemotherapy after radical nephroureterectomy improves the survival outcome of high-risk upper tract urothelial carcinoma patients with cardiovascular comorbidity. Sci Rep. 2020;10:17674. (PMID: 10.1038/s41598-020-74940-x330778397572393)
Uroweb - European Association of Urology. EAU Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: Introduction – Uroweb [cited 28 Sep 2022]. Available at: https://uroweb.org/guidelines/upper-urinary-tract-urothelial-cell-carcinoma.
Di Bello F, Jannello L, Siech C, et al. Adjuvant systemic therapy improved survival after radical nephroureterectomy for upper tract urothelial carcinoma. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-15814-8 . (PMID: 10.1245/s10434-024-15814-83937784511236841)
Seisen T, Krasnow RE, Bellmunt J, Rouprêt M, Leow JJ, Lipsitz SR, et al. Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma. J Clin Oncol. 2017;35(8):852–60. (PMID: 10.1200/JCO.2016.69.414128045620)
No Comments.